Stock of the Day

January 14, 2022

IQVIA (IQV)

$151.70
+$4.33 (+2.9%)
Market Cap: $26.19B

About IQVIA

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.

IQVIA Bull Case

Here are some ways that investors could benefit from investing in IQVIA Holdings Inc.:

  • The current stock price is around $139, which may present a buying opportunity for investors looking for value in the medical research sector.
  • IQVIA Holdings Inc. reported a strong quarterly earnings result, with earnings per share (EPS) of $2.70, exceeding analyst expectations, indicating robust financial performance.
  • The company has a solid market capitalization of approximately $24.06 billion, reflecting its significant presence and stability in the industry.
  • With a return on equity of 28.81%, IQVIA demonstrates effective management and profitability, which can be attractive to investors seeking high returns.
  • Analysts have a consensus rating of "Moderate Buy" for IQVIA, suggesting positive sentiment and potential for future growth in the stock price.

IQVIA Bear Case

Investors should be bearish about investing in IQVIA Holdings Inc. for these reasons:

  • The stock has experienced volatility, with a 1-year high of $252.88 and a low of $134.65, indicating potential risks associated with price fluctuations.
  • IQVIA has a relatively high debt-to-equity ratio of 2.12, which may raise concerns about financial leverage and the company's ability to manage its debt effectively.
  • Recent analyst downgrades, including a reduction in price targets by firms like Barclays and HSBC, suggest a cautious outlook on the stock's near-term performance.
  • The current ratio and quick ratio are both at 0.84, indicating potential liquidity issues that could affect the company's short-term financial health.
  • Despite recent revenue growth, the overall market conditions and competition in the life sciences sector could pose challenges to sustained performance.
← Previous Stock of the DayNext Stock of the Day →

Recent News